ArticleBMJ open2024

Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study).

Yuehong Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.